Photo by atikahakhtar from unsplash
Conventional analyses present aggregate data, masking late responders and efficacy reductions. Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin (IL)‐17A, shows sustained efficacy in moderate‐to‐severe psoriasis. Click to show full abstract
Conventional analyses present aggregate data, masking late responders and efficacy reductions. Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin (IL)‐17A, shows sustained efficacy in moderate‐to‐severe psoriasis.
Keywords:
secukinumab associated;
associated high;
retention regain;
high retention;
continued treatment;
treatment secukinumab
Journal Title: British Journal of Dermatology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: British Journal of Dermatology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!